Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Emeritus Professor Angela Vincent received the Research Recognition Award, clinical science, at the annual meeting of the American Epilepsy Society.

Angela Vincent at a lectern

The AES is a medical and scientific society whose members are dedicated to advancing research and education for preventing, treating and curing epilepsy. The AES  Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. The awards recognise professional excellence reflected in a distinguished history of research of important promise for the improved understanding and treatment of epilepsy. These awards include a $10,000 honorarium.The clinical science award was shared by Angela Vincent and J Dalmau.

As an honorary consultant in immunology, Angela Vincent established and directed the Oxford Neuroimmunology Service from 1992-2016. She was president of the International Society of Neuroimmunology (2001-2004), Head of the Department of Clinical Neurology (2005- 2008), and associate editor of Oxford Academic's Brain (2004-2013).

Although she is not a neurologist, Professor Vincent received the 2009 Association of British Neurologists medal and the 2017 World Federation for Neurology (WFN) Medal for scientific contributions to neurology. In 2018, she received the Klaus Joachim Zülch Prize with two other doctors. She was elected Fellow of the Academy of Medical Sciences in 2002 and Fellow of the Royal Society of London in 2011.

Angela's interests include clinical and serological studies on patients with neuromuscular junction disorders and acquired disorders of the central nervous system associated with antibodies to receptors, ion channels and associated proteins, which causes a wide range of issues including amnesia, seizures, psychiatric and movement disorders. She also pioneered the role of maternal antibodies in causing neuronal pathology that could influence susceptibility to developmental and other neurological diseases. She received her M.B.B.S. and M.Sc. in biochemistry from University College of London.

Similar stories

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Little understood brain region linked to how we perceive pain

A new DPAG-led review paper, published in the journal Brain, has shown that a poorly understood region of the brain called the claustrum may play an important role in how we experience pain.

New funding awarded to study persistent pain in inflammatory arthritis

The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.

First-in-human implant of a “closed-loop” bioelectronic research system for investigating treatments for brain disorders

Researchers at Oxford University have implanted a novel closed-loop research platform for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in Parkinson’s-like Multiple Systems Atrophy (MSA).

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.